Back to Atlas
APotentially durableStandard research/education caution
CMP-0147
Investigational
UBX1325
Senolytic / BCL-xL
Senescent-cell reduction for retinal disease positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- BCL-xL inhibition in senescent retinal cells
- Primary market use
- Ophthalmology / senolytics
Pharmacology
- Molecular weight (Da)
- 1159.69
- Oral bioavailability
- N/A; intravitreal/local ocular
- Half-life
- Local ocular PK not consistently disclosed
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical
- Clinical status
- Investigational
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Ocular local delivery may improve risk-benefit versus systemic BCL-xL inhibitors